The Food and Drug Administration (FDA) has granted traditional approval to Calquence (acalabrutinib) with bendamustine and Rituxan (rituximab) for adults with previously untreated mantle cell lymphoma ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...